ACADIA Pharmaceuticals Stock (NASDAQ: ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock, Quote.Headers.trade-ideas

ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Dell Technologies

Long Ideas

News

Markets

Media

Trading Ideas

ACAD

DELL

LCID

SOFI

UWMC

Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&amp;G Foods, Lucid, SoFi, Dell, Johnson &amp; Johnson, UWM and Symbotic.

Jim Cramer Believes In Dell CEO, Doesn&#39;t Like B&amp;G Foods

Biotech

Mid Cap

General

AXSM

JAZZ

Axsome Therapeutics&#39; (NASDAQ: AXSM) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder, making it the first approved drug in the company&#39;s portfolio.

Axsome Banks on Auvelity &amp; Sunosi to Fuel Growth

airbnb shutter

Pre-Market Outlook

Movers

ABNB

CYRX

EXPE

LYFT

NVRO

PGNY

REAL

RIVN

TREX

TRIP

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals Inc

ACADIA PHARMACEUTICALS ORD

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports and Outdoors Inc

ACADIA ENERGY CORP by Acadia Energy Corporation

Acadia Energy Corp

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

Acadia Realty Trust

ACADIAN TIMBER CORP ORD by Acadian Timber Corp

Acadian Timber Corp

Axcelead DDP has already been engaged in multiple drug discovery projects in the neuroscience area to identify candidate compounds since October 2022. Acadia and Axcelead DDP have entered into the Master Service Agreement so that Axcelead DDP can more efficiently and comprehensively support certain new drug discovery projects of Acadia. Axcelead DDP will provide drug discovery support to Acadia by leveraging its integrated drug discovery platform, deep knowledge and extensive experience in drug discovery research to potentially generate high-quality candidate compounds.
A new drug discovery project under the executed MSA has been launched at the same time. Axcelead DDP will receive an upfront fee, research funding and milestone fees as in the previous projects. Details of the financial terms regarding the Master Service Agreement and the new project are not disclosed.

Contracts

Axcelead Drug Discovery Partners Enters Into Master Service Agreement For Drug Discovery Projects With Acadia Pharmaceuticals To Support Their Goal Of Discovering And Developing Innovative And Novel Medicines To Help Address Unmet Medical Needs; No Financial Terms Disclosed

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer called e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) &#8220;without a doubt, one of the most shorted stocks in the market.&#8221;
&#8220;And every time anything bad happens in the cosmetic group, people<a href="https://www.benzinga.com/quote/ELF/news"> </a>come down on it, but then <a href="https://www.benzinga.com/quote/ELF/news">you have to buy,&#8221; he said.</a>
Cramer said he doesn't like B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>). &#8220;It's just really a bunch of warmed over brands put together under one roof. That game doesn't work anymore,&#8221; he added.
The &#8220;Mad Money&#8221; host said Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) has &#8220;just had a major move up. Every time it's had a major move up, it then moves down.&#8221; He recommended waiting until it comes down a little bit. &#8220;It's too high for me,&#8221; he added.
Cramer recommended to wait for a pullback, when asked about UWM Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NASDAQ">UWMC</a>).
Cramer recommended not touching Symbotic Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NYSE">SYM</a>). &#8220;The company is not the one you want to be in. It is too high, even after this comedown,&#8221; he noted.
ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) is a trading stock and not an investment stock, Cramer said. &#8220;It's just too high risk for me,&#8221; he added.
&#8220;I am believing that SoFi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) may be the right one,&#8221; Cramer said. &#8220;I see the risk reward to be very positive.&#8221;
Cramer said he believes in Michael Dell, CEO of Dell, and recommended buying Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>).
Cramer recommended selling Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
Price Action:
<ul>
<li>E.l.f Beauty shares fell 8.7% to settle at $156.09 on Monday.</li>
<li>Acadia Pharmaceuticals shares gained 0.9% to close at $16.09.</li>
<li>B&amp;G Foods shares gained 2.6% to close at $8.63.</li>
<li>Lucid shares gained 1.4% to settle at $4.26 on Monday.</li>
<li>SoFi shares gained 2% to settle at $7.67.</li>
<li>Dell shares 0.3% to close at $111.67.</li>
<li>Johnson &amp; Johnson shares rose 0.3% to settle at $164.61 on Monday.</li>
<li>UWM shares fell 2% to close at $9.33.</li>
<li>Symbotic shares fell 2.5% to settle at $22.77.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40551343/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods

On August 20, a recent SEC filing unveiled that STEPHEN DAVIS, CEO at ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) made an insider sell.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001070494/000141588924021724//Archives/edgar/data/1070494/000141588924021724/0001415889-24-021724-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that DAVIS executed a sale of 31,747 shares of ACADIA Pharmaceuticals with a total value of $485,094.
The latest update on Wednesday morning shows ACADIA Pharmaceuticals shares up by 0.39%, trading at $15.63.
<h3>Unveiling the Story Behind ACADIA Pharmaceuticals</h3>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals: A Financial Overview</h3>
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 46.44%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 92.47%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): ACADIA Pharmaceuticals's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.2.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.11, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 81.95 is lower than the industry average, implying a discounted valuation for ACADIA Pharmaceuticals's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.89, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 62.42, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001070494">Check Out The Full List Of ACADIA Pharmaceuticals's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

CEO At ACADIA Pharmaceuticals Sells $485K Of Stock

Brendan Teehan, EVP at ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), disclosed an insider sell on August 20, according to a recent SEC filing.
What Happened: Teehan's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001070494/000141588924021726//Archives/edgar/data/1070494/000141588924021726/0001415889-24-021726-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled the sale of 9,534 shares of ACADIA Pharmaceuticals. The total transaction value is $145,679.
The latest update on Wednesday morning shows ACADIA Pharmaceuticals shares up by 0.39%, trading at $15.63.
<h3>About ACADIA Pharmaceuticals</h3>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals's Economic Impact: An Analysis</h3>
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 46.44%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 92.47%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): ACADIA Pharmaceuticals's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.2.
</li>
</ul>
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 81.95 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.89, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 62.42, ACADIA Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001070494">Check Out The Full List Of ACADIA Pharmaceuticals's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVP Of ACADIA Pharmaceuticals Sold $145K In Stock

Revealing a significant insider sell on August 20, Mark Schneyer, EVP at ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), as per the latest SEC filing.
What Happened: After conducting a thorough analysis, Schneyer sold 9,733 shares of ACADIA Pharmaceuticals. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001070494/000141588924021731//Archives/edgar/data/1070494/000141588924021731/0001415889-24-021731-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total transaction value is $148,720.
During Wednesday's morning session, ACADIA Pharmaceuticals shares up by 0.39%, currently priced at $15.63.
<h3>About ACADIA Pharmaceuticals</h3>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals: A Financial Overview</h3>
Revenue Growth: ACADIA Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 46.44%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: With a high gross margin of 92.47%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): ACADIA Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.2.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.11, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 81.95 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 2.89 is lower than the industry average, implying a discounted valuation for ACADIA Pharmaceuticals's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 62.42, ACADIA Pharmaceuticals presents an attractive value opportunity.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001070494">Check Out The Full List Of ACADIA Pharmaceuticals's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Mark Schneyer Implements A Sell Strategy: Offloads $148K In ACADIA Pharmaceuticals Stock

Axsome Therapeutics&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder, making it the first approved drug in the company&#39;s portfolio.
The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand. The momentum is likely to continue for the remainder of 2024.
Axsome is also conducting several label expansion studies on Auvelity targeting other central nervous system&nbsp;disorders like Alzheimer&#39;s disease (AD) associated agitation and smoking cessation.
Currently, two separate phase III studies are evaluating Auvelity for treating agitation associated with AD. Top-line data from both studies are expected later in the second half of 2024.
AXSM is planning to initiate a phase II/III pivotal study on AXS-05 for smoking cessation later in 2024.
The successful development and subsequent commercialization of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.
Axsome acquired U.S. rights to Sunosi, a commercialized drug targeting narcolepsy, from Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome&#39;s portfolio to two marketed drugs. In the first half of 2024, Sunosi&#39;s net product sales were $42.2 million, reflecting an increase of almost 35.2% year over year. Sunosi has become an important revenue driver for Axsome.
In February 2023, AXSM entered into a licensing agreement with Pharmanovia to market Sunosi in Europe and certain Middle East/North African countries. Axsome receives royalties on Sunosi sales in out-licensed territories.
Axsome has an impressive portfolio of pipeline candidates, including AXS-07, AXS-12 and AXS-14. All of these are being developed for various CNS indications.
AXS-07 is being developed for the acute treatment of migraine. After several delays, the company resubmitted its NDA for AXS-07 to the FDA for the acute treatment of migraine in the second quarter of 2024. A decision from the regulatory body is expected within six months.
Though Axsome is riding on the success of Auvelity and Sunosi, competition looms large on the company in the target market as many companies are developing treatments to address various CNS disorders. One such company is Acadia Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acad#NASDAQ">ACAD</a>), which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications.
ACAD&#39;s Nuplazid is already approved for hallucinations and delusions associated with Parkinson&#39;s disease psychosis.
Acadia is also studying pimavanserin for the treatment of other CNS disorders.
<a href="https://www.zacks.com/stock/news/2322688/axsome-axsm-banks-on-auvelity-sunosi-to-fuel-growth?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2322688">To read this article on Zacks.com click here.</a>

Axsome Banks on Auvelity & Sunosi to Fuel Growth

Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $30 to $23.

Price Target

Analyst Ratings

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $23

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $25 to $23.

UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $23

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $27 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $30 to $28.

Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $28

Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Overweight and lowers the price target from $37 to $28.

Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $28

RBC Capital analyst Gregory Renza maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and lowers the price target from $29 to $26.

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $26

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Wednesday.
Shares of Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) dipped 15.8% to $109.68 after the company reported worse-than-expected second-quarter EPS results and issued third-quarter revenue <a href="https://www.benzinga.com/markets/equities/24/08/40213199/why-airbnb-stock-is-down-16-in-wednesday-pre-market">guidance below estimates</a>.
Airbnb's second-quarter sales of $2.748 billion exceeded the analyst consensus estimate of $2.738 billion, marking a 10.63% increase from the same period last year. However, the company's quarterly GAAP earnings of 86 cents per share fell short of the analyst consensus estimate of 92 cents, missing the mark by 6.52%.
ZoomInfo Technologies shares dipped 15.2% to $8.31 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares dipped 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares declined 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>National Vision Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) dipped 24.8% to $10.50 in pre-market trading following weak quarterly sales.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares slipped 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
<li>The RealReal, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) dipped 19.4% to $2.50 in pre-market trading following second-quarter results.</li>
<li>Trex Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) fell 16.7% to $63.75 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) dipped 16.7% to $15.70 following second-quarter results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) fell 16.5% to $21.48 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) fell 15.4% to $13.80 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) shares declined 14.2% to $9.41 following second-quarter financial results.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) dipped 8.1% to $13.60 after the company reported worse-than-expected quarterly adjusted EPS results.</li>
<li>Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) dipped 6.2% to $84.78 following weak quarterly sales.</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) fell 3.8% to $113.05.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $26.0, a high estimate of $31.00, and a low estimate of $20.00. A 7.96% drop is evident in the current average compared to the previous average price target of $28.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1723032080_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of ACADIA Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Keith Tapper</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ACADIA Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ACADIA Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ACADIA Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About ACADIA Pharmaceuticals</h2>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining ACADIA Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 73.75% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ACADIA Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 3.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ACADIA Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 2.06%. This signifies efficient management of assets and strong financial health.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts

WIIM

ACADIA Pharmaceuticals shares are trading lower. The company reported Q2 financial results. Morgan Stanley downgraded the stock to Equal-Weight following the report.

Morgan Stanley analyst Jeffrey Hung downgrades ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) from Overweight to Equal-Weight and lowers the price target from $28 to $20.

Downgrades

Morgan Stanley Downgrades ACADIA Pharmaceuticals to Equal-Weight, Lowers Price Target to $20

Guidance

Acadia Pharmaceuticals Sees FY24 Total Revenue $930M-$980M vs $953.15M Est.

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.18 by 11.11 percent. This is a 1900 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $241.963 million which beat the analyst consensus estimate of $235.418 million by 2.78 percent. This is a 46.44 percent increase over sales of $165.235 million the same period last year.

Earnings

Earnings Beats

ACADIA Pharmaceuticals Q2 2024 GAAP EPS $0.20 Beats $0.18 Estimate, Sales $241.963M Beat $235.418M Estimate

ACADIA Pharmaceuticals shares are trading lower. The company reported Q2 financial results.

Acadia Pharmaceuticals Announces Continued Improvements In RSBQ And CGI-I Scores With Long-Term DAYBUE Treatment In Phase 3 LAVENDER And LILAC Studies; DAYBUE Safety Profile Consistent With LAVENDER Trial Findings; Published Results Show Improved Rett Symptoms In Patients Completing LILAC-1 And LILAC-2 Open-Label Extension Studies

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on ACAD stock, giving a Buy rating today. Tessa Romero's rating is based on a ...

Buy Rating Justified by ACADIA Pharmaceuticals' Solid Performance and Promising Market Expansion

ACADIA Pharma cut at Morgan Stanley on Daybue miss

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report...

ACADIA Pharmaceuticals (ACAD) Gets a Hold from Bank of America Securities

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $28.00....

Nuplazid's Strong Performance and Revised Daybue Guidance Prompt 'Buy' Rating for ACADIA Pharmaceuticals

In a report released on August 6, Joel Beatty from Robert W. Baird maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with...

ACADIA Pharmaceuticals: A Strong Buy on Growing Daybue Adoption and Nuplazid's Market Expansion

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Voyager Therapeutics (VYGR – Research Report), Amg...

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Amgen (AMGN) and ACADIA Pharmaceuticals (ACAD)

3 Biotech Names To Target Now

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Biotechnology company Stoke Therapeutics ($STOK) is grabbing investors' attention with its Zorevunersen (STK-001) treatment for Dravet syndrome, a ...

Stoke Therapeutics (STOK) Stock Surges on Potential Genetic Treatment Breakthrough

Tracking Baker Brothers Portfolio - Q2 2024 Update

ABBV

ABCL

AKRO

AMGN

ARGNF

ARGX

BCRX

BCYC

BEIGF

BGNE

DVAX

EWTX

FOLD

IMCR

INCY

INSM

KYMR

MDGL

RARE

REPL

ROIV

RVMD

RVMDW

RYTM

STOK

VYGR

Press Releases

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (ACAD) Forecast

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock, Quote.Headers.trade-ideas